
Research Topics
Training Areas
Education
Ph.D, University of Massachusetts at Amherst
M.S., Institute of Microbiology, Chinese Academy of Sciences
B.S., Nankai University
Biography
Our laboratory studies genetic and epigenetic regulation of embryonic stem cell pluripotency and somatic cell reprogramming, using genomic and proteomics approaches.
For more information, please visit the Wang Laboratory website.
Research
Specific Clinical/Research Interest:Biochemical Basis and Regulatory Circuitries for Pluripotency of Embryonic Stem Cells
Wang Lab Personnel:
Chandra P. Shekar, Ph.D.
Title:Postdoctoral Fellow
Nationality: India
Research Interest: Novel pluripotency factors for stem cell pluripotency and development
Email: prabhc01@mssm.edu
Francesco Faiola, Ph.D.
Title: Postdoctoral Fellow
Nationality: Italian
Research Interest: Protein-Protein Interaction and Stem Cell Pluripotency
Email: francesco.faiola@mssm.edu
Junjun Ding, Ph.D.
Title: Postdoctoral Fellow
Nationality: China
Research Interest: Epigenetic regulation of stem cell pluripotency
Email: junjun.ding@mssm.edu
Former members:
June 2009-July 2010
Sarah H. Orkin, B.S.
Title: Research Coordinator
Nationality: United States
Research Interest: Technician and lab manager
Summary of Research Studies:
Embryonic stem (ES) cells serve as a potentially inexhaustible source for tissue replacement in regenerative medicine due to their capability of unlimited self-renewal and multi-lineage differentiation. Vital cellular functions of ES cells require the coordinated action of a large number of proteins that assemble into an array of multi-protein complexes of distinct composition and structure (protein-protein interactions).In addition, physical interactions between regulatory pluripotency transcription factors and their target genes (protein-DNA interactions) provide insights into differential gene expression dictating the pluripotency program. Analysis of protein complexes encompassing intricate protein-protein and regulatory protein-DNA interactions is key to understanding stem cell pluripotency.
Recently, we tested the utility of in vivo biotinylation of transcription factors in mouse ES cells, and have established an in vivo biotinylation system for BirA-mediated specific biotinylation of critical pluripotency factors in mouse ES cells. We developed and optimized an approach for affinity purification of pluripotency protein complexes involving streptavidin capture of biotinylated proteins (dubbed bioSAIP) and demonstrated the feasibility of in vivo biotinylation for mapping global/chromosomal targets of many different transcription factors (dubbed bioChIP-chip). Utilizing the technologies we developed, we have constructed a protein interaction network surrounding the pluripotency factor Nanog in mouse ES cells (Wang et al., Nature 2006) and mapped an extended transcriptional network for pluripotency of mouse ES cells (Kim et al. Cell 2008). The network is highly enriched for factors known to be critical in ES cell biology and appears to function as a module for pluripotency. Pluripotency is maintained by many transcription factors that form a highly interconnected protein interaction network including the two homeobox proteins Nanog and Oct4, and a battery of associated proteins of known and unknown functions linking to multiple co-repressor pathways.
Further dissection of the pluripotency network in human ES cells (and induced pluripotent stem cells) and understanding molecular function of the novel factors should illuminate fundamental properties of stem cells and the process of cellular reprogramming, and ultimately lead to precise manipulation and realization of the full clinical therapeutic benefits of these unique cells. Therefore, my lab will be focusing on the following three research areas:
1) Defining protein-protein and protein-DNA interaction networks for pluripotency of human ES cells (and human iPS cells);
2) Dissecting molecular action of novel pluripotency factors on stem cell self-renewal and pluripotency;
3) Elucidating functional significance of novel pluripotency factors in early development and somatic cell reprogramming.
For more information, please visit the Wang Laboratory website.
Publications
Wang J. Efficient Gene Knockdowns in Mouse Embryonic Stem Cells Using MicroRNA-Based shRNAs. Methods Mol Biol. 2010;(650): 241-256.
Wang J, Cantor AB, Orkin SH. Tandem affinity purification of protein complexes in mouse embryonic stem cells using in vivo biotinylation. Current Protocol in Stem Cell Biology 2009;(Chapter 1): Unit 1B.5-1B.5.17.
Kim J, Cantor AB, Orkin SH, Wang J. Use of in vivo biotinylation both protein-protein and protein-DNA interaction networks in mouse embryonic stem cells. Nature Protocols 2009;(4): 506-517.
Orkin SH, Wang J, Kim J, Chu J, Rao S, Theunissen TW, Shen X, Levasseur DN. The transcriptional network controlling pluripotency in ES cells. Cold Spring Harbor Symposia on Quantitative Biology 2008;(73): 195-202.
Wang J, Trowbridge JJ, Rao S, Orkin SH. Proteomic studies of stem cells. (edited by Bernstein, B. E. and Lemischka, I.), published online in stembook.org. Stembook 2008;(1.4.1).
Wang J, Levasseur DN, Orkin SH. Requirement of Nanog dimerization for stem cell self-renewal and pluripotency. Proc. Natl. Acad. Sci. USA 2008; 105(17): 6326-6331.
Kim J, Chu J, Shen X, Wang J, Orkin SH. An extended transcriptional network for pluripotency of embryonic stem cells. Cell 2008; 132(6): 1049-1061.
Levasseur DN, Wang J, Dorschner MO, Stamatoyannopoulos JA, Orkin SH. Oct4 dependence of chromatin structure within the extended Nanog locus in ES cells. Genes and Development 2008; 22(5): 575-580.
Wang J, Orkin SH. A protein roadmap to pluripotency and faithful reprogramming. Cells Tissues Organs 2008; 188(1-2): 23-30.
Wang J, Theunissen TW, Orkin SH. Site-directed, virus-free and inducible RNAi in embryonic stem cells. Proc. Natl. Acad. Sci. USA 2007; 104: 20850-20855.
Ackerman KG, Wang J, Luo L, Fujiwara Y, Orkin SH, Beier DR. Gata4 is necessary for normal pulmonary lobar development. Am J Respir Cell Mol Biol 2007; 36: 391-397.
Wang J, Rao S, Chu J, Shen X, Levasseur DN, Theunissen TW, Orkin SH. A protein interaction network for pluripotency of embryonic stem cells. Nature 2006; 444: 364-368.
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Wang did not report having any of the following types of financial relationships with industry during 2012 and/or 2013: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
Atran Berg Laboratory Building Floor AB7 Room 10D
1428 Madison Avenue
New York, NY 10029
Fax: 212-241-3518



